![](https://www.prospertrading.com/wp-content/uploads/2019/02/Fountain-Of-Youth-961x641.jpg)
Evolus Inc (EOLS) shares are up sharply today after the company gained FDA approval for their flagship product, Jeuveau, a cosmetic injection used to reduce the appearance of wrinkles on the face. This means Jeuveau is a direct competitor to Botox, which of course is a big seller for its parent company, Allergan. Here’s a recap.